To hear about similar clinical trials, please enter your email below
Trial Title:
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
NCT ID:
NCT05733013
Condition:
Thyroid Cancer
Thyroid
Refractory Thyroid Cancer
Conditions: Official terms:
Thyroid Neoplasms
Thyroid Diseases
Conditions: Keywords:
RAI refractory thyroid cancer
thyroid cancer
thyroid
Refractory Thyroid Cancer
Radio-iodine refractory thyroid cancer
22-320
Memorial Sloan Kettering Cancer Center
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
Surveillance Visit
Description:
Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance
of medication and adverse events will be recorded in every visit.
Arm group label:
Participants with refractory thyroid cancer patients
Summary:
The purpose of this study to learn more about the use of redifferentiating medications as
a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is
a registry study.
Criteria for eligibility:
Study pop:
All patients eligible to receive a redifferentiating agent in the adjuvant setting or in
the treatment of structural metastatic disease not enrolled in a clinical trial will be
approached for recruitment. All eligible patients will enroll in the study and will be
followed indefinitely after enrollment.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients ≥ 18 years old at time of consent
Inclusion Criteria:
- Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI.
- Patients who will receive redifferentiation agents prior to planned diagnostic
and/or therapeutic use of radioactive iodine as part of routine clinical care.
- Patients who have never received redifferentiation agents outside of a clinical
trial or have received redifferentiation agents in the context of a clinical trial
will be enrolled after the clinical team has decided to proceed with a
redifferentiation agent as part of routine clinical care prior to diagnostic and/or
therapeutic radioactive iodine administration.
- Patients previously treated with redifferentiation agents as part of clinical care
prior to diagnostic and/or therapeutic radioactive iodine administration who are
willing to provide retrospectively collected data surrounding the time of the
previous treatment and will provide prospective data from the time of consent.
Exclusion Criteria:
- RAI refractory thyroid cancer patients that will receive redifferentiation agents
prior to diagnostic and/or therapeutic use of radioactive iodine as part of a
prospective clinical trial.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Memorial Sloan Kettering Cancer Center
Address:
City:
New York
Zip:
10065
Country:
United States
Status:
Recruiting
Contact:
Last name:
Laura Boucai, PhD
Phone:
646-608-3906
Start date:
February 7, 2023
Completion date:
February 7, 2028
Lead sponsor:
Agency:
Memorial Sloan Kettering Cancer Center
Agency class:
Other
Source:
Memorial Sloan Kettering Cancer Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05733013
http://www.mskcc.org
